SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ghettogoulash who wrote (62987)1/7/2025 4:41:03 AM
From: ghettogoulash1 Recommendation

Recommended By
rodneyh07

  Read Replies (1) of 63304
 
Originally, the company was exploring the use of their own proprietary bio-based CMF for PET caps and closures, but soon realized they could implement a quicker solution using existing PET. I am in awe of this talent and how quickly they have knocked out the machinery and ramped it up when everyone else has failed . Even so, Origin's bio-based CMF (and HTC) is still the ultimate goal for not only caps and closures, but bottles and jars and everything else. They just cannot produce the feedstock yet at scale on their own.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News